Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Chevron has reversed course sharply since the earnings release on May 27, with the stock falling 6.4% on the week to $184.71 — erasing almost the entire pre-earnings rally and leaving the stock fractionally below where it traded a month ago.
The price action is the story this week. CVX is now 14% below the mean analyst target of $215.87, having given back the bulk of the $197 level reached heading into results. The move is broadly in line with the energy complex: XOM fell 6.7% on the week, COP dropped 6.4%, and DVN was the hardest hit at 9.1%. The higher-beta independents led the selloff just as they led the rally — shed 6.6%. and held up better at roughly 3% each, benefiting from downstream and hedging exposure. CVX's decline, while painful, is closer to the sector average than an outlier.
Options traders signalled the defensiveness before the fall. The put/call ratio is running at 0.85 — about 1.9 standard deviations above its 20-day average of 0.79 — and is closing in on its 52-week high of 0.93. That degree of protective positioning is unusual for a mega-cap integrated name, and in retrospect reflected genuine unease ahead of the print. The borrow market, by contrast, remains completely untroubled: availability is at its maximum recorded level, with over 1.7 billion shares available to borrow against roughly 18 million shorted. Cost to borrow is 0.32%, barely changed on the week. Short interest itself is negligible at 0.91% of free float — a level that has remained essentially flat through the selloff. There is no short-covering tailwind, but equally no crowded bear trade.
The Street's reaction to results has been constructive at the margin, which makes the price decline harder to dismiss as purely analyst-driven. Mizuho lifted its target to $230 just this morning, maintaining Outperform. Barclays raised to $213 yesterday from $192 while holding Equal-Weight — notably, Barclays had already lifted from $180 to $192 on May 4, so this is a second consecutive upward revision. Morgan Stanley edged its target up to $214 earlier in the week. The direction of travel is upward across most desks. Only Bernstein moved in the opposite direction, trimming to $204 from $216 on May 11. The consensus mean of $215.87 now implies 17% upside from current levels — wider than it has been in recent months. The bull case rests on FCF growth from two key upstream assets and a 4% dividend yield that ranks in the 96th percentile for income quality. The bear case centres on crude price sensitivity and execution risk in international operations.
One ownership detail worth flagging: John B. Hess, who joined the Chevron board following the Hess Corporation acquisition, sold approximately $73 million worth of CVX shares on May 20 across multiple tranches at prices between $192 and $197. The sales came near the recent high and just ahead of the earnings-driven selloff. The trades carry a relatively modest significance score, but the timing and scale — combined with continued selling from the same insider at lower prices in early May — make them notable context.
The next earnings date is July 31. Between now and then, the widening gap between the current price and consensus targets, combined with still-elevated options defensiveness, frames the question plainly: whether analysts begin revising targets down toward the stock, or whether the stock recovers toward the targets.
See the live data behind this article on ORTEX.
Open CVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.